Gene and serum markers may predict canakinumab tapering success in sJIA

A study of 79 systemic juvenile idiopathic arthritis (sJIA) patients in remission on canakinumab, part of a randomised withdrawal trial, examined serum and transcriptomic biomarkers linked to tapering outcomes. The study reported that lower serum sCD163, CXCL9, IL-1RA, and IL-18, along with a 9-gene NanoString signature (including ATF6, IL1B, and TNFAIP3), distinguished patients with successful versus unsuccessful drug withdrawal, with the composite gene score achieving an AUC of 0.71. The authors state that combined molecular biomarker profiling may enable individualised tapering strategies for Still's disease.

Most relevant for: Patients with systemic juvenile idiopathic arthritis in clinical remission on canakinumab who are being considered for medication tapering or withdrawal.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.